BioSpace News Archive

Drug Development

A Hit and a Miss for Merck’s Keytruda

Merck posted a rare defeat Wednesday for its blockbuster Keytruda (pembrolizumab) in prostate cancer while simultaneously announcing a victory in biliary tract cancer.

January 25, 2023
·
2 min read
·
Tristan Manalac
Business

As Tech Giants Fall, Tech-Focused VC Fund Rakes in $350M

Three venture capitalists debuted Dimension I Wednesday, a new fund with $350 million to fuel modern biotech.

January 25, 2023
·
1 min read
·
Kate Goodwin
FDA

Recent Regulatory Decisions Highlight Evolution of the Anti-Amyloid Theory

The FDA’s approval of Biogen and Eisai’s Leqembi and subsequent decision not to approve Eli Lilly’s donanemab have sparked debate anew about the anti-amyloid theory in Alzheimer’s.

January 25, 2023
·
3 min read
·
Heather McKenzie
Wet Lab vs Dry Lab: Challenges, Benefits and Skills Required

Wet labs and dry labs perform vastly different functions for biotechs and research organizations, and thus require different skill sets. Read on to find out which lab environment is right for you.

January 25, 2023
·
5 min read
·
Christie Adams
Drug Development

Psychedelic for Depression Moves Forward on Positive Phase IIa Data

Small Pharma announced positive top-line results Wednesday from a Phase IIa study evaluating a short-duration psychedelic for major depressive disorder.

January 25, 2023
·
2 min read
·
Hayley Shasteen
Business

Sosei Heptares Webinar Presentation for FY2022 Financial Results

Sosei Group Corporation will announce its earnings results and present operational highlights for the 12 months ended 31 December 2022 on Tuesday, 14 February 2023.

January 25, 2023
·
3 min read
Policy

Innate Pharma Announces HSR Clearance Regarding Expansion of Its Collaboration With Sanofi on NK Cell Engagers

Innate Pharma SA announced the expiration of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 with respect to the previously announced expansion of its collaboration with Sanofi.

January 25, 2023
·
4 min read
Genetown

Oxurion Announces Second Amendment to Negma Funding Program

Oxurion NV announced that it has further amended its mandatory convertible bonds issuance and subscription agreement with the Negma Group.

January 25, 2023
·
4 min read
Business

Invitation to presentation of BioArctic’s fourth quarter report for October - December 2022 on October 20 at 9.30 a.m. CET

BioArctic AB will publish the company’s fourth quarter report for October - December 2022 on Friday, February 3, 2022, at 08:00 a.m. CET.

January 25, 2023
·
2 min read
Drug Development

VPM oversees clinical trial and translational project management – Positive Phase I data of client Memo Therapeutics AG

Vakzine Projekt Management GmbH announced the successful completion of a clinical client project for Memo Therapeutics AG, Switzerland.

January 25, 2023
·
5 min read